MOL CARCINOGEN 润色咨询

MOLECULAR CARCINOGENESIS

出版年份:1988 年文章数:1469 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:3.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2026-02-04 ms1000001974391603 来自湖南省

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤药理学;生信
    经验分享:投稿时间线
    2025.10.29投稿
    2026.1.3返修
    2026.1.8修回
    2026.1.26接收
    2026.2.2 Proof

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2026-01-08 ms2000001485045977 来自浙江省

    审稿速度:12.0
    偏重的研究方向:肿瘤药物
    经验分享:二审3个月,催稿不回。。。。。。。。。。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2025-02-14 ms8000001999172928

    请问最近的审稿快吗

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2025-03-25 ms2000000248066803 来自甘肃省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:免疫;肿瘤;病理
    经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2025-03-19 ms3000000799396471 来自甘肃省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤基础研究;免疫治疗
    经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。
    3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。
    3.12修回
    3.14接收

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2024-05-15 ms7000000138744330 来自江苏省

    偏重的研究方向:肿瘤
    经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2022-09-21 ms5000000426407939

    偏重的研究方向:肿瘤基础研究;肿瘤;分子机制
    经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快

    20

    展开20条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2025-02-25 ms3000001330760750 来自江苏省

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享:五个月,比较慢

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2023-04-06 ms7000001027936853 来自重庆

    偏重的研究方向:肿瘤;非编码RNA
    经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收

    8

    展开8条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2299688, encodeId=25ba229968845, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤药理学;生信<br>经验分享:投稿时间线<br>2025.10.29投稿<br>2026.1.3返修<br>2026.1.8修回<br>2026.1.26接收<br>2026.2.2 Proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5c35620040, createdName=ms1000001974391603, createdTime=Wed Feb 04 12:54:48 CST 2026, time=2026-02-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2296455, encodeId=c23f22964554b, content=审稿速度:12.0<br>偏重的研究方向:肿瘤药物<br>经验分享:二审3个月,催稿不回。。。。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=075a9469484, createdName=ms2000001485045977, createdTime=Thu Jan 08 20:13:06 CST 2026, time=2026-01-08, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2251878, encodeId=747122518e88c, content=请问最近的审稿快吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29599578753, createdName=ms8000001999172928, createdTime=Fri Feb 14 12:11:33 CST 2025, time=2025-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2257665, encodeId=2afd225e665ae, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤;病理<br>经验分享:12月2 投稿;12月21 一修(3个审稿人,21个问题);2月11返修;3月1 二修(四个问题,都补了实验);3月13返修;3月25接受。总体来说审稿比较严谨,但是审稿速度很快。美中不足,中科院分区从二区变四区了,有分区要求的慎重。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60956413270, createdName=ms2000000248066803, createdTime=Tue Mar 25 15:17:19 CST 2025, time=2025-03-25, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2256703, encodeId=78682256e033f, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤基础研究;免疫治疗<br>经验分享:9.29投稿----期间催稿两次,每两个月一次,态度诚恳,编辑回信很及时,让耐心等待。<br>3.4返修----一个审稿人。7个审稿意见,其中一个让补实验。<br>3.12修回<br>3.14接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1085415084, createdName=ms3000000799396471, createdTime=Wed Mar 19 08:59:45 CST 2025, time=2025-03-19, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2204855, encodeId=cdbd22048553c, content=偏重的研究方向:肿瘤<br>经验分享:投稿一个多月了,从第二天就是under review状态,一直没有变动,也不确定是不是送外审了,着急又不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b1cc8157106, createdName=ms7000000138744330, createdTime=Wed May 15 17:00:51 CST 2024, time=2024-05-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2089443, encodeId=bf24208944309, content=偏重的研究方向:肿瘤基础研究;肿瘤;分子机制<br>经验分享:2022.8.15 投稿; 2022.8.30返回一审意见-Major revision 两个审稿人一共提了七条意见吧大概;其中让补实验的有两条,我应该算完成了不到半条; 2022.9.13 返修; 2022.9.21 接收。 我自己这篇文章感觉其实内容还算蛮多,之前投过2个,一个小小cdd 俩星期未送外审被拒,一个cancer science 秒拒,建议转投这个杂志,投稿流程挺顺畅,审稿速度蛮快, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b376540466, createdName=ms5000000426407939, createdTime=Wed Sep 21 00:07:41 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2253488, encodeId=07892253488e7, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:五个月,比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 25 11:05:05 CST 2025, time=2025-02-25, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2124175, encodeId=691f21241e53a, content=偏重的研究方向:肿瘤;非编码RNA<br>经验分享:22.12.19投稿后第二天under review,等了一个月左右的时候发过一篇邮件询问外审时间,23.2.10返修给了六十天时间补实验,23.3.14修回第二天系统重新变成under review,23.3.31接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=215, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c9f8340253, createdName=ms7000001027936853, createdTime=Thu Apr 06 21:29:23 CST 2023, time=2023-04-06, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2251439, encodeId=64cf225143909, content=审稿速度:3.0 | 投稿命中率:50.0<br>经验分享:历时5个月,感觉比较慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff919433295, createdName=ms3000001330760750, createdTime=Tue Feb 11 13:00:39 CST 2025, time=2025-02-11, status=1, ipAttribution=江苏省)]
    2025-02-11 ms3000001330760750 来自江苏省

    审稿速度:3.0 | 投稿命中率:50.0
    经验分享:历时5个月,感觉比较慢

    0

共183条页码: 1/19页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分